Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Appili Therapeutics Inc. (APLIF : OTC)

• Company Description    Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.07 Daily Weekly Monthly 20 Day Moving Average: 7,397 shares Shares Outstanding: 71.27 (millions) Market Capitalization: $4.80 (millions) Beta: -1.32 52 Week High: $0.90 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.30% -17.11% 12 Week -31.47% -22.98% Year To Date -24.97% -8.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 21-1344 SUMMER ST. - HALIFAX,A5 B3H 0A8 CAN ph: 902-442-4655 fax: - None http://www.appilitherapeutics.com

• General Corporate Information    Officers Armand Balboni - Chief Executive Officer Ian Mortimer - Chairman Kimberly Stephens - Chief Financial Officer Myriam Triest - Director Stephane Paquette - Director Peer Information Appili Therapeutics Inc. (CORR.) Appili Therapeutics Inc. (RSPI) Appili Therapeutics Inc. (CGXP) Appili Therapeutics Inc. (BGEN) Appili Therapeutics Inc. (GTBP) Appili Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03783R107 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/23/22 Share - Related Items Shares Outstanding: 71.27 Most Recent Split Date: (:1) Beta: -1.32 Market Capitalization: $4.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/23/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.20 EPS Growth vs. Year Ago Period: 20.00% vs. Previous Quarter: 71.43% Sales Growth vs. Year Ago Period: 4,721.74% vs. Previous Quarter: 27,625.00% ROE 03/31/22 - - 12/31/21 - -793.06 09/30/21 - -361.19 ROA 03/31/22 - - 12/31/21 - -203.47 09/30/21 - -178.30 Current Ratio 03/31/22 - - 12/31/21 - 1.04 09/30/21 - 0.78 Quick Ratio 03/31/22 - - 12/31/21 - 1.04 09/30/21 - 0.78 Operating Margin 03/31/22 - - 12/31/21 - -1,874.06 09/30/21 - -40,158.18 Net Margin 03/31/22 - - 12/31/21 - -1,874.06 09/30/21 - -40,158.18 Pre-Tax Margin 03/31/22 - - 12/31/21 - -1,863.98 09/30/21 - -39,961.82 Book Value 03/31/22 - - 12/31/21 - 0.00 09/30/21 - -0.05 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©